Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 11
2004 7
2005 10
2006 10
2007 13
2008 20
2009 22
2010 16
2011 23
2012 23
2013 14
2014 21
2015 27
2016 24
2017 21
2018 22
2019 13
2020 20
2021 24
2022 29
2023 28
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

376 results

Results by year

Filters applied: . Clear all
Page 1
A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence.
Bruschi M, Angeletti A, Prunotto M, Meroni PL, Ghiggeri GM; Zeus consortium; Moroni G, Sinico RA, Franceschini F, Fredi M, Vaglio A, Cavalli A, Scapozza L, Patel JJ, Tan JC, Lo KC, Cavagna L, Petretto A, Pratesi F, Migliorini P, Locatelli F, Pazzola G, Pesce G, Giannese D, Manfredi A, Ramirez GA, Esposito P, Murdaca G, Negrini S, Bui F, Trezzi B, Emmi G, Cavazzana I, Binda V, Fenaroli P, Pisan I, Montecucco C, Santoro D, Scolari F, Mescia F, Volpi S, Mosca M, Tincani A, Ravelli A, Murtas C, Candiano G, Caridi G, La Porta E, Verrina E. Bruschi M, et al. Among authors: cavalli a. Autoimmun Rev. 2024 Mar 27;23(5):103535. doi: 10.1016/j.autrev.2024.103535. Online ahead of print. Autoimmun Rev. 2024. PMID: 38552995 Review.
An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer.
Myers SH, Poppi L, Rinaldi F, Veronesi M, Ciamarone A, Previtali V, Bagnolini G, Schipani F, Ortega Martínez JA, Girotto S, Di Stefano G, Farabegoli F, Walsh N, De Franco F, Roberti M, Cavalli A. Myers SH, et al. Among authors: cavalli a. Eur J Med Chem. 2024 Feb 5;265:116114. doi: 10.1016/j.ejmech.2023.116114. Epub 2023 Dec 31. Eur J Med Chem. 2024. PMID: 38194775 Free article.
Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages.
Marcotte H, Cao Y, Zuo F, Simonelli L, Sammartino JC, Pedotti M, Sun R, Cassaniti I, Hagbom M, Piralla A, Yang J, Du L, Percivalle E, Bertoglio F, Schubert M, Abolhassani H, Sherina N, Guerra C, Borte S, Rezaei N, Kumagai-Braesch M, Xue Y, Su C, Yan Q, He P, Grönwall C, Klareskog L, Calzolai L, Cavalli A, Wang Q, Robbiani DF, Hust M, Shi Z, Feng L, Svensson L, Chen L, Bao L, Baldanti F, Xiao J, Qin C, Hammarström L, Yang X, Varani L, Xie XS, Pan-Hammarström Q. Marcotte H, et al. Among authors: cavalli a. Proc Natl Acad Sci U S A. 2024 Jan 16;121(3):e2315354120. doi: 10.1073/pnas.2315354120. Epub 2024 Jan 9. Proc Natl Acad Sci U S A. 2024. PMID: 38194459 Free PMC article.
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86.
Zuo F, Cao Y, Sun R, Yisimayi A, Du L, Bertoglio F, Schubert M, Guerra C, Cavalli A, Hust M, Robbiani DF, Abolhassani H, Xie XS, Hammarström L, Marcotte H, Pan-Hammarström Q. Zuo F, et al. Among authors: cavalli a. Lancet Infect Dis. 2024 Jan;24(1):e7-e9. doi: 10.1016/S1473-3099(23)00732-6. Epub 2023 Dec 7. Lancet Infect Dis. 2024. PMID: 38071989 No abstract available.
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ, Gaudio E, Napoli S, Yvon Herbaux CJ, Tarantelli C, Bordone RP, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F. Arribas AJ, et al. Among authors: cavalli a. bioRxiv [Preprint]. 2023 Nov 16:2023.11.14.566994. doi: 10.1101/2023.11.14.566994. bioRxiv. 2023. PMID: 38014209 Free PMC article. Preprint.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Isolation and Characterization of Monomeric Human RAD51: A Novel Tool for Investigating Homologous Recombination in Cancer.
Rinaldi F, Schipani F, Balboni B, Catalano F, Marotta R, Myers SH, Previtali V, Veronesi M, Scietti L, Cecatiello V, Pasqualato S, Ortega JA, Girotto S, Cavalli A. Rinaldi F, et al. Among authors: cavalli a. Angew Chem Int Ed Engl. 2023 Dec 18;62(51):e202312517. doi: 10.1002/anie.202312517. Epub 2023 Nov 20. Angew Chem Int Ed Engl. 2023. PMID: 37924230
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
376 results